A novel immuno-therapeutic platform in development: AbstimX™
In preclinical studies, scientists at Network Immunology Inc. have discovered how to treat and prevent the development of allergic disease and inflammatory colitis with Network Immunology's proprietary immuno-therapeutic technology and product in development, AbstimX™.
Further, in one pilot study, a similar approach was administered and seen to be effective in preventing the development of inflammatory breast cancer in the mouse model.
Network Immunology welcomes collaborators and accredited investors to be a part of this venture.
For investment information, please contact George Hoffmann at email@example.com.